DigestRedComo funciona
Red
/
Empresas
Id
No verificado

Idorsia Pharmaceuticals Ltd

Sobre qué escribimos

Anuncios brevesFarmacéutica

52 Comunicados de prensa

Ver todos los comunicados de prensa
10/11/2025
Farmacéutica
Anuncios breves
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
05/11/2025
Farmacéutica
Anuncios breves
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
29/10/2025
Farmacéutica
Anuncios breves
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
09/10/2025
Farmacéutica
Anuncios breves
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
09/10/2025
Farmacéutica
Anuncios breves
Idorsia launches an offering of registered shares – to fund the company to overall profitability
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
21/09/2025
Farmacéutica
Anuncios breves
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
18/09/2025
Farmacéutica
Anuncios breves
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
10/09/2025
Farmacéutica
Anuncios breves
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
08/09/2025
Farmacéutica
Anuncios breves
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
04/09/2025
Farmacéutica
Anuncios breves
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0